Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021021699 - TARGETED NITROXIDE COMPOUNDS AND THEIR USE IN TREATING FERROPTOSIS-RELATED DISEASES

Publication Number WO/2021/021699
Publication Date 04.02.2021
International Application No. PCT/US2020/043682
International Filing Date 27.07.2020
IPC
C07D 211/94 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
92with a hetero atom directly attached to the ring nitrogen atom
94Oxygen atom, e.g. piperidine N-oxide
C07D 405/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07C 291/02 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
291Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/-C07C281/144
02containing nitrogen-oxide bonds
A61K 31/445 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
A61K 31/4468 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4468having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61K 31/453 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
453containing a six-membered ring with oxygen as a ring hetero atom
Applicants
  • UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US]/[US]
Inventors
  • WIPF, Peter
  • MASKREY, Taber, Sarah
  • LAPORTE, Matthew, G.
  • CHARASCHANYA, Manwika
Agents
  • HIRSHMAN, Jesse, A.
  • JACKSON, Brian, J.
  • FORTNEY, Lester, N.
  • CANNONI, Ann, M.
Priority Data
62/879,00126.07.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TARGETED NITROXIDE COMPOUNDS AND THEIR USE IN TREATING FERROPTOSIS-RELATED DISEASES
(FR) COMPOSÉS DE NITROXYDE CIBLÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES LIÉES À LA FERROPTOSE
Abstract
(EN)
Provided herein are compounds useful in the prevention or treatment of ferroptosis in a patient, and methods of preventing or treating ferroptosis, or a treating a condition or disease associated with ferroptosis, such as a patient having a neurodegenerative disease, traumatic brain injury, acute kidney disease, liver injury, ischemia/reperfusion injury, ischemic stroke, intracerebral hemorrhage, liver fibrosis, diabetes, acute myeloid leukemia, age-related macular degeneration, psoriasis, a hemolytic disorder, or an inflammatory disease.
(FR)
L'invention concerne des composés utiles dans la prévention ou le traitement de la ferroptose chez un patient, et des méthodes de prévention ou de traitement de la ferroptose, ou le traitement d'une affection ou d'une maladie associée à la ferroptose, comme un patient présentant une maladie neurodégénérative, une lésion cérébrale traumatique, une maladie rénale aiguë, une lésion hépatique, une lésion ischémique/de reperfusion, un accident vasculaire cérébral ischémique, une hémorragie intracérébrale, une fibrose hépatique, le diabète, une leucémie myéloïde aiguë, une dégénérescence maculaire liée à l'âge, le psoriasis, un trouble hémolytique, ou une maladie inflammatoire.
Latest bibliographic data on file with the International Bureau